Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 293

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location

Open access
Karremann, Michael, Gielen, Gerrit H, Hoffmann, Marion, Wiese, Maria, Colditz, Niclas, Warmuth-Metz, Monika, Bison, Brigitte, Claviez, Alexander, van Vuurden, Dannis G, von Bueren, André O, Gessi, Marco, Kühnle, Ingrid, Hans, Volkmar H, Benesch, Martin, Sturm, Dominik, Kortmann, Rolf-Dieter, Waha, Andreas, Pietsch, Torsten, Kramm, Christof M·2018·Neuro-Oncology

Abstract

Background: The novel entity of "diffuse midline glioma, H3 K27M-mutant" has been defined in the 2016 revision of the World Health Organization (WHO) classification of tumors of the central nervous system (CNS). Tumors of this entity arise in CNS midline structures of predominantly pediatric patients and are associated with an overall dismal prognosis. They are defined by K27M mutations in H3F3A or HIST1H3B/C, encoding for histone 3 variants H3.3 and H3.1, respectively, which are considered hallmark events driving gliomagenesis. Methods: Here, we characterized 85 centrally reviewed diffuse gliomas on midline locations enrolled in the nationwide pediatric German HIT-HGG registry regarding tumor site, histone 3 mutational status, WHO grade, age, sex, and extent of tumor resection. Results: We found 56 H3.3 K27M-mutant tumors (66%), 6 H3.1 K27M-mutant tumors (7%), and 23 H3-wildtype tumors (27%). H3 K27M-mutant gliomas shared an aggressive clinical course independent of their anatomic location. Multivariate regression analysis confirmed the significant impact of the H3 K27M mutation as the only independent parameter predictive of overall survival (P = 0.009). In H3 K27M-mutant tumors, neither anatomic midline location nor histopathological grading nor extent of tumor resection had an influence on survival. Conclusion: These results substantiate the clinical significance of considering diffuse midline glioma, H3 K27M-mutant, as a distinct entity corresponding to WHO grade IV, carrying a universally fatal prognosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/neuonc/nox149

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 293

Metadata

Authors
Karremann, M., Gielen, G. H., Hoffmann, M., Wiese, M., Colditz, N., Warmuth-Metz, M., Bison, B., Claviez, A., van Vuurden, D. G., von Bueren, A. O., Gessi, M., Kühnle, I., Hans, V. H., Benesch, M., Sturm, D., Kortmann, R.-D., Waha, A., Pietsch, T., & Kramm, C. M.
Venue
Neuro-Oncology
Published
2017-08-04
Volume
20
Issue
1
Pages
123-131
ISSN
  • 1522-8517 (ISSN-L)
  • 1523-5866
OpenAlex
W2742224451
Cited by
293
References
32
FWCI
12.45
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location. https://app.cochat.ai/papers/10.1093/neuonc/nox149
The paper
Karremann, M., Gielen, G. H., Hoffmann, M., Wiese, M., Colditz, N., Warmuth-Metz, M., Bison, B., Claviez, A., van Vuurden, D. G., von Bueren, A. O., Gessi, M., Kühnle, I., Hans, V. H., Benesch, M., Sturm, D., Kortmann, R.-D., Waha, A., Pietsch, T., & Kramm, C. M. (2018). Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location. Neuro-Oncology. https://doi.org/10.1093/neuonc/nox149

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.